Skip to content
Our Latest News, Case Studies, Webinars & More
The Business Case for Modern Slavery and Human Rights Compliance in Australia
Australia’s Modern Slavery Act 2018 (Cth) requires thousands of companies to report annually on how they identify and manage risks of modern slavery in their operations and supply chains.[...]
What the new BIS 50% Rule Means for Third-Party Screening & Ownership Due Diligence
On September 29, 2025, the Bureau of Industry and Security of the US Department of Commerce (“BIS”) issued a new interim final rule [...]
The Importance of TPRM in Facilitating Ethical Transactions with HCPs
In the Life Sciences industry, maintaining ethical and transparent relationships with healthcare professionals (HCPs) is fundamental to trust, patient safety, and business integrity. [...]
Agility, Innovation & Strong (Ethical) Foundations
Earlier this month, Ethixbase360 was delighted to sponsor the third annual Risk & Compliance Pharma & Life Sciences Conference, held in London. [...]
CSDDD in Transition – Has the EU Omnibus Package Gone Too Far? What’s Next for Companies and Human Rights Compliance
As debate continues over the EU Omnibus Proposal—unlikely to be finalized before 2026—many companies are questioning whether the package has […]
The Case for Integrity: How SMEs Can Leverage Ethical Business Practices for Growth
In today’s business environment, where regulators and customers are increasingly vigilant about transparency and integrity, ethical business practices have shifted from a compliance
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape The pharmaceutical and life sciences industry […]
Tariffs, Trade, and Terrorism: Navigating Third-Party Due Diligence in a Shifting Risk Landscape
Global trade is under unprecedented scrutiny. From tariffs and export controls to sanctions and terrorism designations, the compliance risks facing […]
